Mylan Launches Generic Version of Faslodex Injection in the US

Mylan Launches Generic Version of Faslodex Injection in the US
The U.S. Food and Drug Administration has approved Mylan's generic version of AstraZeneca's Faslodex injection to be used for the same breast cancer indications as the original product, the company announced. The approval makes Mylan's Fulvestrant injection the third generic version of Faslodex, following the approval of Sandoz's and Glenmark Pharmaceuticals' products. A generic version of a therapy contains the same active chemical substance as an approved brand-name drug and, therefore, has the same medical profile with regards to dosage, safety, manner of administration, and performance. However, generics are usually sold at significantly lower prices than the original product, making treatments accessible to more patients. "Mylan's launch of Fulvestrant Injection represents an important addition to our growing oncology portfolio and, more importantly, expands the available treatment options for women who are facing advanced or metastatic stages of breast cancer," Rajiv Malik, president of Mylan, said in a
Subscribe or to access all post and page content.